Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer
Posted on 2019-01-30 - 05:00
Abstract Objectives To apply a systems pathology-based approach to the quantification of nuclear Active β-catenin and human leukocyte antigen class I, and assess the biomarker involvement in a cohort of prostate tumor patients. Results The systems pathology approach applied allows a precise quantification of the marker expression in the different cell compartments as well as the determination of the areas that coexpress two markers. Our data shows that the accumulation of β-catenin in the nuclear compartment is significantly decreased in the adjacent normal areas when compared to tumor of the same patients (p < 0.001). In conclusion, the application of this novel multiple immunofluorescence assay demonstrates that the upregulation of Active β-catenin is a relatively common feature of prostate tumor development, and further supports the activation of the Wnt/β-catenin pathway in prostate cancer progression.
CITE THIS COLLECTION
DataCiteDataCite
No result found
Puig, Pere; Erill, Nadina; Terricabras, Marta; Subirana, Isaac; González-García, Judit; Asensi-Puig, Adrià; et al. (2019). Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer. figshare. Collection. https://doi.org/10.6084/m9.figshare.c.4384670.v1